+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030

  • ID: 5446046
  • Report
  • September 2021
  • Region: Global
  • 175 Pages
  • The Business Research Company

FEATURED COMPANIES

  • Amgen
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Merck
  • Puma Biotechnology
Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global breast cancer monoclonal antibodies (mabs) market.







This report focuses on the breast cancer monoclonal antibodies (mabs) market which is experiencing strong growth. The report gives a guide to the breast cancer monoclonal antibodies (mabs) market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for breast cancer monoclonal antibodies (mabs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Breast Cancer Monoclonal Antibodies (mAbs) market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider breast cancer monoclonal antibodies (mabs) market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The breast cancer monoclonal antibodies (mabs) market section of the report gives context. It compares the breast cancer monoclonal antibodies (mabs) market with other segments of the breast cancer monoclonal antibodies (mabs) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, breast cancer monoclonal antibodies (mabs) indicators comparison.

Scope


Markets Covered:


  • By Product: Naked Mabs; Conjugated Mabs
  • By End-User: Hospitals; Retail Pharmacies
  • By Treatment: Chemotherapy; Surgery & Radiation Therapy; Targeted Therapy; Biologic Therapy; Hormone Therapy

Companies Mentioned:


Amgen; Mylan; Merck; Novartis; GlaxoSmithKline

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Breast Cancer Monoclonal Antibodies Market

What is the estimated value of the Global Breast Cancer Monoclonal Antibodies Market?

The Global Breast Cancer Monoclonal Antibodies Market was estimated to be valued at $13.8 billion in 2021.

What is the growth rate of the Global Breast Cancer Monoclonal Antibodies Market?

The growth rate of the Global Breast Cancer Monoclonal Antibodies Market is 7.8%, with an estimated value of $18.6 billion by 2025.

What is the forecasted size of the Global Breast Cancer Monoclonal Antibodies Market?

The Global Breast Cancer Monoclonal Antibodies Market is estimated to be worth $18.6 billion by 2025.

Who are the key companies in the Global Breast Cancer Monoclonal Antibodies Market?

Key companies in the Global Breast Cancer Monoclonal Antibodies Market include Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim and Myers Squibb.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Merck
  • Puma Biotechnology

1. Executive Summary2. Breast Cancer Monoclonal Antibodies Market Characteristics3. Breast Cancer Monoclonal Antibodies Market Trends and Strategies4. Impact Of COVID-19 On Breast Cancer Monoclonal Antibodies
5. Breast Cancer Monoclonal Antibodies Market Size and Growth
5.1. Global Breast Cancer Monoclonal Antibodies Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Breast Cancer Monoclonal Antibodies Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Breast Cancer Monoclonal Antibodies Market Segmentation
6.1. Global Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Naked Mabs
  • Conjugated Mabs
6.2. Global Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospitals
  • Retail Pharmacies
6.3. Global Breast Cancer Monoclonal Antibodies Market, Segmentation by Treatment, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Chemotherapy
  • Surgery & Radiation therapy
  • Targeted therapy
  • Biologic therapy
  • Hormone therapy

7. Breast Cancer Monoclonal Antibodies Market Regional and Country Analysis
7.1. Global Breast Cancer Monoclonal Antibodies Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Breast Cancer Monoclonal Antibodies Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Breast Cancer Monoclonal Antibodies Market
8.1. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Breast Cancer Monoclonal Antibodies Market
9.1. China Breast Cancer Monoclonal Antibodies Market Overview
9.2. China Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Breast Cancer Monoclonal Antibodies Market
10.1. India Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Breast Cancer Monoclonal Antibodies Market
11.1. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Breast Cancer Monoclonal Antibodies Market
12.1. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Breast Cancer Monoclonal Antibodies Market
13.1. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Breast Cancer Monoclonal Antibodies Market
14.1. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Breast Cancer Monoclonal Antibodies Market
15.1. Western Europe Breast Cancer Monoclonal Antibodies Market Overview
15.2. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Breast Cancer Monoclonal Antibodies Market
16.1. UK Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Breast Cancer Monoclonal Antibodies Market
17.1. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Breast Cancer Monoclonal Antibodies Market
18.4. France Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Breast Cancer Monoclonal Antibodies Market
19.1. Eastern Europe Breast Cancer Monoclonal Antibodies Market Overview
19.2. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Breast Cancer Monoclonal Antibodies Market
20.1. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Breast Cancer Monoclonal Antibodies Market
21.1. North America Breast Cancer Monoclonal Antibodies Market Overview
21.2. North America Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Breast Cancer Monoclonal Antibodies Market
22.1. USA Breast Cancer Monoclonal Antibodies Market Overview
22.2. USA Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Breast Cancer Monoclonal Antibodies Market
23.1. South America Breast Cancer Monoclonal Antibodies Market Overview
23.2. South America Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Breast Cancer Monoclonal Antibodies Market
24.1. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Breast Cancer Monoclonal Antibodies Market
25.1. Middle East Breast Cancer Monoclonal Antibodies Market Overview
25.2. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Breast Cancer Monoclonal Antibodies Market
26.1. Africa Breast Cancer Monoclonal Antibodies Market Overview
26.2. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation by End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Breast Cancer Monoclonal Antibodies Market Competitive Landscape and Company Profiles
27.1. Breast Cancer Monoclonal Antibodies Market Competitive Landscape
27.2. Breast Cancer Monoclonal Antibodies Market Company Profiles
27.2.1. Amgen
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Mylan
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Merck
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Novartis
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. GlaxoSmithKline
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Breast Cancer Monoclonal Antibodies Pipeline Analysis29. Key Mergers and Acquisitions in the Breast Cancer Monoclonal Antibodies Market30. Breast Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Merck
  • Puma Biotechnology
Major players in the breast cancer monoclonal antibodies (mAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma.

The global breast cancer monoclonal antibodies market is expected to grow from $12.67 billion in 2020 to $13.76 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $18.61 billion in 2025 at a CAGR of 8%.

The breast cancer monoclonal antibodies (mAbs) market consists of sales of monoclonal antibodies by entities (organizations, sole traders and partnerships) that produce breast cancer monoclonal antibodies used as therapy for breast cancer either as monotherapy or combination therapy. The revenue generated includes the sales of naked mAbs and conjugated mAbs. The companies engaged in the breast cancer monoclonal antibodies market are primarily focused on the research, development, and production of monoclonal antibodies that are used in early-stage and advanced breast cancer, ductal carcinoma in-situ, triple-negative breast cancer, inflammatory breast cancer, and others.

The breast cancer monoclonal antibodies market covered in this report is segmented by product into naked mAbs, conjugated mAbs and by end-user into hospitals, retail pharmacies.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to impact the revenues of breast cancer monoclonal antibodies manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many herbs used in Ayurveda have anti-cancer properties. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes, affecting the sales of oncology drugs. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027. The National Institute of Cancer indicated the promising results of vaccines in HER2-positive cancer including breast, ovarian, lung, colorectal, and gastroesophageal cancers, wherein they have used patients’ immune cells to treat their HER2-positive cancers by genetically modifying them to customize personalized vaccine. These factors are expected to continue during the forecast period and limit the demand for the breast cancer monoclonal antibodies market.

In March 2019, AstraZeneca, a UK-based global biopharmaceutical company that discovers, develops and commercializes prescription drugs in therapy areas such as oncology, cardiovascular, renal & metabolism and respiratory, entered into a collaboration with Daiichi Sankyo Company, Limited with an upfront payment of $1.35 billion. The collaboration agreement is about the global development and commercialization of trastuzumab deruxtecan (DS-8201), which is an exclusive antibody-drug conjugate (ADC) and potential new targeted cancer therapy. Except in Japan (exclusive rights for Daiichi Sankyo), the companies will jointly develop and commercialize trastuzumab deruxtecan. Daiichi Sankyo Company Limited is a Japan-based global pharmaceutical company that creates innovative new and generic medicines and new methods of drug discovery and delivery.

Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibodies market’s growth. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the US. This includes women currently being treated and women who have completed the treatment. According to the American cancer society, approximately 500 men and 41,760 women died of breast cancer in 2019. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibodies market.

Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. In February 2019, the FDA approved the combination of a mAb trastuzumab with hyaluronidase-oysk for SC administration in HER2-positive early breast cancer wherein hyaluronidase is an enzyme that helps the body to use trastuzumab. In 2020, The American Society of Clinical Oncology published the success of combination therapy of a targeted monoclonal antibody atezolizumab with chemotherapy with improved progression-free survival in patients with triple-negative breast cancer. It resulted in the progression-free survival of 7.2 months for patients receiving the combination therapy, compared with 5.5 months for those who received placebo plus nab-paclitaxel (chemotherapy). Promising results with targeted therapies and combination therapies are expected to raise the focus on these therapies in the breast cancer monoclonal antibodies market.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Amgen
  • Mylan
  • Merck
  • Novartis
  • GlaxoSmithKline
  • Daiichi Sankyo
  • Biocad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Array BioPharma
  • Celldex Therapeutics
  • Celltrion
  • Roche
  • Immunomedics
  • MacroGenics
  • Pfizer
  • Sun Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Puma Biotechnology
  • Seattle Genetics
  • AstraZeneca
  • Eddingpharm
  • Eisai
  • Galena Biopharma
  • ImmunoGen
Note: Product cover images may vary from those shown

Loading
LOADING...